Produced by Araxis Merge on 6/14/2018 2:30:44 PM Eastern Daylight Time. See www.araxis.com for information about Merge. This report uses XHTML and CSS2, and is best viewed with a modern standards-compliant browser. For optimum results when printing this report, use landscape orientation and enable printing of background images and colours in your browser.
| # | Location | File | Last Modified |
|---|---|---|---|
| 1 | EPIP_2.0_PSS_1.0_227.zip | Acrobat Document.docx | Wed Jun 13 12:18:03 2018 UTC |
| 2 | EPIP_2.0_PSS_1.0_227.zip | Acrobat Document.docx | Thu Jun 14 02:04:01 2018 UTC |
| Description | Between Files 1 and 2 |
|
|---|---|---|
| Text Blocks | Lines | |
| Unchanged | 13 | 1660 |
| Changed | 10 | 30 |
| Inserted | 0 | 0 |
| Removed | 2 | 9 |
| Whitespace | |
|---|---|
| Character case | Differences in character case are significant |
| Line endings | Differences in line endings (CR and LF characters) are ignored |
| CR/LF characters | Not shown in the comparison detail |
No regular expressions were active.
| 1 | 9830: PSS* 1.0*227 Ma ster Test Plan | ||
| 2 | |||
| 3 | Creation D ate: May 21, 2018 9 :27:26 PM (UTC-05:00 )Last Modi fied: May 25, 2018 9 :10:28 AM (UTC-05:00 ) | ||
| 4 | |||
| 5 | State: App roved | ||
| 6 | Originator :Leckie, D avid R.(Le idos)Owner : Ilustris imo, Lucy (Leidos) P riority: U nassigned | ||
| 7 | Copied Fro m:PSS*1.0* 203 Master Test Plan | ||
| 8 | |||
| 9 | Descriptio n: This Te st Plan de tails the testing pr ocesses an d objectiv es for the Existing Product In take Progr am (EPIP) Patch PSS* 1.0*227. | ||
| 10 | |||
| 11 | Summary | ||
| 12 | |||
| 13 | Categories | ||
| 14 | Product: U nassigned Release: U nassigned Test Phase : Unassign ed | ||
| 15 | |||
| 16 | Business O bjectives, Testing A pproach, T ools and M ethods | ||
| 17 | Business O bjectives | ||
| 18 | This patch addresses the follo wing NSRs and Requi rements: | ||
| 19 | |||
| 20 | NSR2015011 5 Audits f or DRUG fi le 50 Chan ges: | ||
| 21 | EPIC 49781 8: Audit D rug File C hanges – F or VistA P harmacy Ap plications Coordinat ors who su pport the Pharmacy a pplication at multi- divisional facilitie s. The abi lity to re ceive an e -mail (tha t is gener ated to a mail group that I am a member of) whenev er a user makes chan ges to: a) specific fields ass ociated wi th a drug file entry using the Drug Ente r/Edit opt ion; or b) a drug fi le cost vi a any meth od (i.e., Drug Enter /Edit opti ons or Fil eManager). | ||
| 22 | NSR2008071 4 Drug Fil e Price Ch ange Date/ Time Stamp : | ||
| 23 | EPIC 38596 5: Drug Fi le Increas es to Drug File Pric es – Abili ty to know when ther e are incr eases to d rug file p rices and how they a ffect phar macy cost data acros s systems. | ||
| 24 | EPIC 38597 3: Drug Fi le Ability to assess drug file prices as current a nd accurat e – Abilit y to asses s drug fil e prices a s current and accura te. | ||
| 25 | EPIC 38598 0: Drug Fi le Trends and Budget Forecasts – Ability to measur e trends a nd make ac curate bud get foreca sts. | ||
| 26 | EPIC 38597 8: Drug Fi le Ability to report on a pric e change d ate for a select dru g- Ability to report on a pric e change d ate for a select dru g. | ||
| 27 | EPIC 88717 1: Date an d Time Sta mp Drug Fi le Price - For Pharm acy users who manage drug pric es a proce ss to date /time stam p the drug file pric e that aid s the phar macy in ma intaining accurate d rug prices unlike th e current process wh ere there is no prac tical way of assessi ng how cur rent the d rug prices are. | ||
| 28 | |||
| 29 | Testing Ap proach | ||
| 30 | The Existi ng Product Intake Pr ogram (EPI P) Test Te am follows approved Department of Vetera ns Affairs (VA) test ing standa rds and us es authori zed VA too ls, such a s Rational Team Conc ert (RTC) and Ration al Quality Manager ( RQM), to p lan, condu ct, and re cord testi ng activit ies. | ||
| 31 | |||
| 32 | Tools | ||
| 33 | The EPIP T est Team u tilizes RQ M to enter Test Case s /Test sc ripts for all Unit, Regression , Componen t Integrat ion/System , and Func tional tes ts. A Test Execution record is created i n RQM each time a te st is run and the te st results are store d and repo rted in RQ M. Defects found dur ing testin g are ente red and tr acked in t he RTC too l. When ne cessary, S ection 508 testing i s conducte d using th e JAWS scr een reader . | ||
| 34 | |||
| 35 | Methodolog y | ||
| 36 | All tests are execut ed manuall y by the E PIP Test T eam in the designate d EPIP Tes t accounts . Testing is conduct ed on the VistA and CPRS enhan cements in troduced b y the EPIP Developme nt Team, a s well as for impact to existi ng VistA/C PRS functi onality. A ny defects found are resolved | ||
| 37 | by the EPI P Developm ent Team b ased on Se verity and Priority and, once resolved, are retest ed by the Test Team. If issues are found during In tegration testing, t he Test Te am coordin ates any n eeded reso lution wit h VA. When necessary , Section 508 testin g is condu cted by a qualified Section 50 8 test eng ineer and all result s reported to the VA Section 5 08 office. All test documents are develo ped, deliv ered, and stored in accordance with VA s tandards a nd the pro cesses out lined in t he Veteran s Focused Integratio n Process (VIP) Guid e. | ||
| 38 | |||
| 39 | Test Objec tives | ||
| 40 | This Maste r Test Pla n supports the follo wing objec tives: | ||
| 41 | Provide te st coverag e for 100% of the do cumented r equirement s. | ||
| 42 | |||
| 43 | Provide co verage for all testi ng types - Unit, Com ponent Int egration/S ystem, Fun ctional, a nd Regress ion testin g. | ||
| 44 | All test c ases and s cripts wil l be revie wed by the Developme nt and Tes t Leads be fore test execution. | ||
| 45 | Configure test accou nts based on VA requ irements, such as al l released VistA pat ches are i nstalled i n the test accounts so no exis ting code modificati ons are ov erlaid. | ||
| 46 | Test team will execu te 100% of the test cases. | ||
| 47 | Test team will execu te testing using the Rational Quality Ma nager tool , set up t est execut ion record s, and ent er all tes t results. | ||
| 48 | Test team will execu te Test ca ses/Test s cripts in EPIP team test envir onments D1 S1 and D1G 1 for Vist A and CPRS as well a s other Vi stA applic ations imp acted by t he code ch anges. | ||
| 49 | Record all defects f ound durin g testing and track the test v ersions wh ere the de fect was f ound. | ||
| 50 | Provide Ve rifiable O bjective E vidence (V OE) for th e final bu ild. | ||
| 51 | |||
| 52 | Test Data | ||
| 53 | The EPIP T est SQA te am utilize s the Test data avai lable in t he EPIP te st environ ment. All data is en crypted fo llowing th e VA OIT D ata Encryp tion proce ss. | ||
| 54 | |||
| 55 | Examples o f encrypte d Test dat a: AAAFDUH , KUXJB | ||
| 56 | BADHB, HAA DXS CQHSBX QD,UXYI | ||
| 57 | |||
| 58 | Requiremen t Collecti on Links | ||
| 59 | |||
| 60 | |||
| 61 | Suspect Co ntributorS ummary | ||
| 62 | |||
| 63 | |||
| 64 | 969485: Se ction 508 9 - Legacy Software Product 87 0632: PSS* 1.0*227 Re quirements Collectio n | ||
| 65 | |||
| 66 | Developmen t Plan Lin ks | ||
| 67 | |||
| 68 | |||
| 69 | Summary | ||
| 70 | Intake Pro ducts 002- 009 - Spri nt 5 | ||
| 71 | |||
| 72 | |||
| 73 | |||
| 74 | Test Sched ule | ||
| 75 | |||
| 76 | Test Sched ule Table | ||
| 77 | |||
| 78 | |||
| 79 | NameDescri ptionPoint sPlanned D efectsPlan ned Start Date Pla nned End D atePlanned Duration | ||
| 80 | |||
| 81 | Key Dates Table | ||
| 82 | |||
| 83 | |||
| 84 | NameDescri ptionDate | ||
| 85 | |||
| 86 | Software T est Enviro nment Deta ils | ||
| 87 | SQA testin g for all the Intake s included in the PS S*1.0*227 patch is e xecuted in the D1G1 test envir onment. De velopers e xecute the ir Unit te sting in t he EPIP De velopment Test accou nt, D1S1. | ||
| 88 | |||
| 89 | Test Envir onments | ||
| 90 | |||
| 91 | |||
| 92 | Dev1 Silve r1 | ||
| 93 | Type: | ||
| 94 | Virtual Ma chine | ||
| 95 | |||
| 96 | |||
| 97 | Dev1 Gold1 | ||
| 98 | Type: | ||
| 99 | Virtual Ma chine | ||
| 100 | |||
| 101 | Quality Ob jectives | ||
| 102 | |||
| 103 | |||
| 104 | Objective | ||
| 105 | Expected | ||
| 106 | Actual Val ue | ||
| 107 | Status | ||
| 108 | Comments | ||
| 109 | Percentage of Failed | ||
| 110 | Execution Records< 1 00Successf ul | ||
| 111 | |||
| 112 | Number of Blocked | ||
| 113 | Execution Records= 0 0Successfu l | ||
| 114 | |||
| 115 | Defects Re ported= 10 Successful | ||
| 116 | |||
| 117 | |||
| 118 | |||
| 119 | Entry Crit eria | ||
| 120 | |||
| 121 | Objective | ||
| 122 | Expected | ||
| 123 | Actual Val ue | ||
| 124 | Status | ||
| 125 | Comments | ||
| 126 | Test Envir onment Ava ilable | ||
| 127 | = 1 | ||
| 128 | 0 | ||
| 129 | Successful | ||
| 130 | |||
| 131 | Unit Testi ng Complet e | ||
| 132 | = 1 | ||
| 133 | 0 | ||
| 134 | Successful | ||
| 135 | |||
| 136 | Code Modif ication(s) | ||
| 137 | Complete= 1 | ||
| 138 | 0 | ||
| 139 | Successful | ||
| 140 | |||
| 141 | Test Data Available= 1 | ||
| 142 | 0 | ||
| 143 | Successful | ||
| 144 | |||
| 145 | |||
| 146 | Exit Crite ria | ||
| 147 | |||
| 148 | |||
| 149 | Objective | ||
| 150 | Expected | ||
| 151 | Actual Val ue | ||
| 152 | Status | ||
| 153 | Comments | ||
| 154 | Code Modif ication(s) | ||
| 155 | Complete= 10Successf ul | ||
| 156 | |||
| 157 | Test Resul ts Reporte d= 10Succe ssful | ||
| 158 | |||
| 159 | |||
| 160 | Defects Re ported= 10 Successful | ||
| 161 | |||
| 162 | |||
| 163 | |||
| 164 | Test Cases | ||
| 165 | |||
| 166 | |||
| 167 | |||
| 168 | spect | ||
| 169 | |||
| 170 | untID S uPriority NameSt ateOwnerCr eated ByTE R WeightM odified Validates Requireme nts Co | ||
| 171 | |||
| 172 | |||
| 173 | |||
| 174 | 8980 | ||
| 175 | |||
| 176 | PSS*1.0*22 7 - NSR201 50115 - Ed iting | ||
| 177 | Sub- Files in D rug File # 50 Trigger s a MailMa n Message Audit | ||
| 178 | |||
| 179 | |||
| 180 | Approved | ||
| 181 | |||
| 182 | Leckie, Da vid R. (Le idos) | ||
| 183 | Leckie, Da vid R. (Le idos)1 | ||
| 184 | May 22, | ||
| 185 | 2018 (UTC- 05: 00) | ||
| 186 | May 21, | ||
| 187 | |||
| 188 | 868579: PS S*1.0*227 NSR2015011 5 EPIC 497 818 - Audi t | ||
| 189 | Drug File Changes | ||
| 190 | |||
| 191 | 8982 PSS*1.0 *227 - NSR 20080714 - Verifying the DATE PRICE LAST CHANGED f ield | ||
| 192 | |||
| 193 | PSS*1.0*22 7 - NSR 20 080714 - M odify | ||
| 194 | Approved Carey, Wi lliam L. ( Leidos) | ||
| 195 | |||
| 196 | |||
| 197 | Carey, Wil liam L. | ||
| 198 | Leckie, Da vid R. (Le idos)1 | ||
| 199 | Leckie, Da vid R. | ||
| 200 | 2018-- | ||
| 201 | (UTC-05: | ||
| 202 | 00) | ||
| 203 | May 21, | ||
| 204 | 2018 | ||
| 205 | |||
| 206 | 8984 | ||
| 207 | |||
| 208 | |||
| 209 | |||
| 210 | 8980 | ||
| 211 | |||
| 212 | |||
| 213 | |||
| 214 | PSS*1.0*22 7 - NSR201 50115 and | ||
| 215 | Carey, Wil liam L. | ||
| 216 | Leckie, Da vid R. | ||
| 217 | May 21, | ||
| 218 | 20188981 | ||
| 219 | |||
| 220 | |||
| 221 | 8981 | ||
| 222 | parameter to enter N umber of M onths to R etain Data | ||
| 223 | |||
| 224 | PSS*1.0*22 7 - NSR201 50115 - Re naming | ||
| 225 | a Pr oduct in D rug File # 50 Trigger s a MailMa n Message Audit | ||
| 226 | |||
| 227 | |||
| 228 | NSR2 0080714 - Editing a drug and r eceiving M AILMAN mes sage | ||
| 229 | |||
| 230 | PSS*1.0*22 7 - NSR201 50115 - Ad ding a New | ||
| 231 | Prod uct in Dru g File #50 Triggers a MailMan Message Au dit | ||
| 232 | Approved | ||
| 233 | |||
| 234 | |||
| 235 | |||
| 236 | Approved | ||
| 237 | |||
| 238 | |||
| 239 | |||
| 240 | Approved | ||
| 241 | |||
| 242 | |||
| 243 | |||
| 244 | Approved | ||
| 245 | (Leidos) | ||
| 246 | |||
| 247 | |||
| 248 | Leckie, Da vid R. (Le idos) | ||
| 249 | |||
| 250 | |||
| 251 | |||
| 252 | (Leidos) | ||
| 253 | |||
| 254 | |||
| 255 | Leckie, Da vid R. (Le idos) | ||
| 256 | (Leidos)1 | ||
| 257 | Leckie, Da vid R. (Le idos)1 | ||
| 258 | (Leidos)1 | ||
| 259 | Leckie, Da vid R. (Le idos)1 | ||
| 260 | (UTC-05: 0 0) | ||
| 261 | May 22, | ||
| 262 | 2018 (UTC- 05: 00) | ||
| 263 | |||
| 264 | |||
| 265 | (UTC-05: 0 0) | ||
| 266 | May 22, | ||
| 267 | 2018 (UTC- 05: 00) | ||
| 268 | May 21, | ||
| 269 | -- | ||
| 270 | |||
| 271 | |||
| 272 | |||
| 273 | |||
| 274 | -- | ||
| 275 | |||
| 276 | |||
| 277 | 868579: PS S*1.0*227 NSR2015011 5 EPIC 497 818 - Audi t | ||
| 278 | Drug File Changes | ||
| 279 | |||
| 280 | 8979 PSS*1.0 *227 - Aud its for Dr ug File 50 Changes a nd Drug Fi le Price C hange/Time Stamp | ||
| 281 | |||
| 282 | |||
| 283 | 8980 PSS*1.0 *227 - NSR 20150115 - Edits in Drug | ||
| 284 | File #50 T riggers a MailMan Me ssage Audi t | ||
| 285 | |||
| 286 | PSS*1.0*22 7 - NSR201 50115 - Vi ewing a | ||
| 287 | Approved Leckie, David R. | ||
| 288 | (Leidos) | ||
| 289 | |||
| 290 | |||
| 291 | Approved Leckie, David R. | ||
| 292 | (Leidos) | ||
| 293 | |||
| 294 | |||
| 295 | Leckie, Da vid R. | ||
| 296 | Leckie, Da vid R. (Le idos)1 | ||
| 297 | Leckie, Da vid R. (Le idos)1 | ||
| 298 | Leckie, Da vid R. | ||
| 299 | 2018 (UTC- 05: 00) | ||
| 300 | May 22, | ||
| 301 | 2018 (UTC- 05: 00) | ||
| 302 | May 22, | ||
| 303 | 2018 | ||
| 304 | -- | ||
| 305 | |||
| 306 | |||
| 307 | 868579: PS S*1.0*227 NSR2015011 5 EPIC 497 818 - Audi t | ||
| 308 | Drug File Changes | ||
| 309 | |||
| 310 | 868579: PS S*1.0*227 | ||
| 311 | |||
| 312 | 8980 | ||
| 313 | |||
| 314 | |||
| 315 | |||
| 316 | |||
| 317 | PSS*1.0*22 7 - NSR201 50115 and | ||
| 318 | Carey, Wil liam L. | ||
| 319 | Leckie, Da vid R. | ||
| 320 | May 21, | ||
| 321 | 20188981 | ||
| 322 | Product in Drug File #50 Trigg ers a Mail Man Messag e Audit | ||
| 323 | |||
| 324 | |||
| 325 | NSR2008071 4 - Editin g MAILMAN GROUP and | ||
| 326 | Assigning Users | ||
| 327 | Approved | ||
| 328 | |||
| 329 | |||
| 330 | |||
| 331 | Approved | ||
| 332 | (Leidos) | ||
| 333 | |||
| 334 | |||
| 335 | |||
| 336 | (Leidos) | ||
| 337 | (Leidos)1 | ||
| 338 | (Leidos)1 | ||
| 339 | (UTC-05: 0 0) | ||
| 340 | |||
| 341 | |||
| 342 | (UTC-05: 0 0) | ||
| 343 | May 21, | ||
| 344 | NSR2015011 5 EPIC 497 818 - Audi t | ||
| 345 | Drug File Changes | ||
| 346 | |||
| 347 | |||
| 348 | -- | ||
| 349 | |||
| 350 | 8984 PSS*1.0 *227 - NSR 20080714 - Verify Hi storical P rice Data | ||
| 351 | |||
| 352 | |||
| 353 | 8980 PSS*1.0 *227 - Aud its for Dr ug File 50 Changes a nd Drug Fi le Price C hange/Time Stamp | ||
| 354 | |||
| 355 | |||
| 356 | |||
| 357 | |||
| 358 | |||
| 359 | |||
| 360 | |||
| 361 | 8981 PSS*1.0 *227 - NSR 20080714 - Drug File Price | ||
| 362 | Change Dat e/Time Sta mp | ||
| 363 | Approved Carey, Wi lliam L. ( Leidos) | ||
| 364 | |||
| 365 | |||
| 366 | Approved Leckie, David R. | ||
| 367 | (Leidos) | ||
| 368 | |||
| 369 | |||
| 370 | |||
| 371 | |||
| 372 | |||
| 373 | |||
| 374 | |||
| 375 | Approved Leckie, David R. | ||
| 376 | (Leidos) | ||
| 377 | Leckie, Da vid R. (Le idos)1 | ||
| 378 | Leckie, Da vid R. (Le idos)1 | ||
| 379 | |||
| 380 | |||
| 381 | |||
| 382 | |||
| 383 | |||
| 384 | Leckie, Da vid R. (Le idos)1 | ||
| 385 | 2018 (UTC- 05: 00) | ||
| 386 | May 21, | ||
| 387 | 2018 (UTC- 05: 00) | ||
| 388 | |||
| 389 | |||
| 390 | |||
| 391 | |||
| 392 | May 22, | ||
| 393 | 2018 (UTC- 05: 00) | ||
| 394 | -- | ||
| 395 | |||
| 396 | |||
| 397 | |||
| 398 | -- | ||
| 399 | |||
| 400 | |||
| 401 | |||
| 402 | ID SuPr iority Name | ||
| 403 | State | ||
| 404 | Owner | ||
| 405 | Created By | ||
| 406 | TER | ||
| 407 | Co | ||
| 408 | Weight | ||
| 409 | Modified Validate s Requirem ents | ||
| 410 | |||
| 411 | |||
| 412 | |||
| 413 | |||
| 414 | |||
| 415 | |||
| 416 | |||
| 417 | |||
| 418 | |||
| 419 | |||
| 420 | |||
| 421 | |||
| 422 | |||
| 423 | |||
| 424 | |||
| 425 | |||
| 426 | |||
| 427 | |||
| 428 | |||
| 429 | |||
| 430 | |||
| 431 | 8981 | ||
| 432 | |||
| 433 | |||
| 434 | |||
| 435 | |||
| 436 | |||
| 437 | |||
| 438 | |||
| 439 | |||
| 440 | |||
| 441 | |||
| 442 | |||
| 443 | |||
| 444 | |||
| 445 | |||
| 446 | |||
| 447 | |||
| 448 | |||
| 449 | |||
| 450 | |||
| 451 | PSS*1.0*22 7 - NSR200 80714 - Mo dify | ||
| 452 | Para meter to E nter Numbe r of Month s to Retai n Data | ||
| 453 | |||
| 454 | |||
| 455 | |||
| 456 | |||
| 457 | |||
| 458 | |||
| 459 | |||
| 460 | |||
| 461 | |||
| 462 | |||
| 463 | |||
| 464 | |||
| 465 | |||
| 466 | |||
| 467 | |||
| 468 | |||
| 469 | |||
| 470 | |||
| 471 | |||
| 472 | |||
| 473 | Approved | ||
| 474 | |||
| 475 | |||
| 476 | |||
| 477 | |||
| 478 | |||
| 479 | |||
| 480 | |||
| 481 | |||
| 482 | |||
| 483 | |||
| 484 | |||
| 485 | |||
| 486 | |||
| 487 | |||
| 488 | |||
| 489 | |||
| 490 | |||
| 491 | |||
| 492 | |||
| 493 | |||
| 494 | Leckie, Da vid R. (Le idos) | ||
| 495 | |||
| 496 | |||
| 497 | |||
| 498 | |||
| 499 | |||
| 500 | |||
| 501 | |||
| 502 | |||
| 503 | |||
| 504 | |||
| 505 | |||
| 506 | |||
| 507 | |||
| 508 | Leckie, Da vid R. (Le idos)1 | ||
| 509 | |||
| 510 | |||
| 511 | |||
| 512 | |||
| 513 | |||
| 514 | |||
| 515 | |||
| 516 | |||
| 517 | |||
| 518 | |||
| 519 | |||
| 520 | |||
| 521 | |||
| 522 | |||
| 523 | |||
| 524 | |||
| 525 | |||
| 526 | |||
| 527 | |||
| 528 | May 22, | ||
| 529 | 2018 (UTC- 05: 00) | ||
| 530 | |||
| 531 | spect | ||
| 532 | |||
| 533 | unt | ||
| 534 | |||
| 535 | |||
| 536 | |||
| 537 | |||
| 538 | |||
| 539 | Test Suite s | ||
| 540 | |||
| 541 | IDPriority Name | ||
| 542 | Created By | ||
| 543 | State | ||
| 544 | Owner | ||
| 545 | Weight | ||
| 546 | Modified | ||
| 547 | Executions | ||
| 548 | |||
| 549 | |||
| 550 | |||
| 551 | |||
| 552 | |||
| 553 | May 21, | ||
| 554 | |||
| 555 | 7034 | ||
| 556 | EPIP PSS*1 .0*227 - U nit Testin g | ||
| 557 | Leckie, Da vid R.(Lei dos) | ||
| 558 | Approved | ||
| 559 | Carey, Wil liam L. (L eidos) | ||
| 560 | 100 | ||
| 561 | 2018 (UTC- | ||
| 562 | 05:00) | ||
| 563 | 1 | ||
| 564 | |||
| 565 | |||
| 566 | |||
| 567 | |||
| 568 | |||
| 569 | |||
| 570 | May 22, | ||
| 571 | |||
| 572 | 7035 | ||
| 573 | EPIP PSS*1 .0*227 - F unctional Testing | ||
| 574 | Leckie, Da vid R.(Lei dos) | ||
| 575 | Approved | ||
| 576 | Leckie, Da vid R.(Lei dos) | ||
| 577 | 100 | ||
| 578 | 2018 (UTC- | ||
| 579 | 05:00) | ||
| 580 | 1 | ||
| 581 | |||
| 582 | 7036 | ||
| 583 | EPIP PSS* 1.0*277 - Regression | ||
| 584 | |||
| 585 | Leckie, Da vid R.(Lei dos) | ||
| 586 | |||
| 587 | Approved | ||
| 588 | |||
| 589 | Leckie, Da vid R.(Lei dos) | ||
| 590 | |||
| 591 | 100 | ||
| 592 | May 25, | ||
| 593 | 2018 (UTC- | ||
| 594 | |||
| 595 | 1 | ||
| 596 | |||
| 597 | Testing | ||
| 598 | |||
| 599 | |||
| 600 | |||
| 601 | |||
| 602 | 05:00) | ||
| 603 | |||
| 604 | |||
| 605 | |||
| 606 | |||
| 607 | |||
| 608 | |||
| 609 | |||
| 610 | May 24, | ||
| 611 | |||
| 612 | 7037 | ||
| 613 | EPIP PSS*1 .0*227 - C omponent | ||
| 614 | Leckie, Da vid R.(Lei dos) | ||
| 615 | Approved | ||
| 616 | Leckie, Da vid R.(Lei dos) | ||
| 617 | 100 | ||
| 618 | 2018 (UTC- | ||
| 619 | 1 | ||
| 620 | |||
| 621 | Integratio n and Syst em Testing | ||
| 622 | |||
| 623 | |||
| 624 | |||
| 625 | |||
| 626 | 05:00) | ||
| 627 | |||
| 628 | |||
| 629 | Test Suite Execution Records | ||
| 630 | |||
| 631 | |||
| 632 | ID | ||
| 633 | Priority | ||
| 634 | Name | ||
| 635 | Test Suite | ||
| 636 | Test | ||
| 637 | Environmen t | ||
| 638 | Iteration | ||
| 639 | Owner | ||
| 640 | Created By | ||
| 641 | Last Resul tTest Plan | ||
| 642 | |||
| 643 | |||
| 644 | |||
| 645 | |||
| 646 | 308810 | ||
| 647 | |||
| 648 | EPIP PSS*1 .0*227 | ||
| 649 | - Componen t I ntegration | ||
| 650 | and System Testing_D ev1 Gold1 | ||
| 651 | EPIP PSS*1 .0*277 | ||
| 652 | |||
| 653 | |||
| 654 | 7037:EPIP PSS*1. | ||
| 655 | 0*227 - Co mponent In tegration and System Testing | ||
| 656 | |||
| 657 | |||
| 658 | |||
| 659 | 7036:EPIP PSS*1. | ||
| 660 | |||
| 661 | |||
| 662 | |||
| 663 | Dev1 Gold1 Unassigned Leckie, Da vid R. (Le idos) | ||
| 664 | |||
| 665 | |||
| 666 | |||
| 667 | |||
| 668 | |||
| 669 | Leckie, Da vid R. | ||
| 670 | |||
| 671 | |||
| 672 | |||
| 673 |
|
||
| 674 | |||
| 675 | |||
| 676 | 9830:PSS | ||
| 677 | 0*227 | ||
| 678 | Master Tes t Plan | ||
| 679 | |||
| 680 | |||
| 681 | 9830:PSS | ||
| 682 | 0*227 | ||
| 683 | |||
| 684 | 308812 | ||
| 685 | - Regressi on Testing _Dev1 Gold 1 | ||
| 686 | EPIP PSS*1 . | ||
| 687 | 0*277 - Re gression T esting | ||
| 688 | Dev1 Gold1 Unassigned | ||
| 689 | (Leidos)
|
||
| 690 | Master Tes t Plan | ||
| 691 | |||
| 692 | 9830:PSS | ||
| 693 | |||
| 694 | 308815 | ||
| 695 | |||
| 696 | |||
| 697 | |||
| 698 | |||
| 699 | 308823 | ||
| 700 | 0*227 - Un it Testing _Dev1 | ||
| 701 | Gold1 | ||
| 702 | EPIP PSS*1 .0*227 | ||
| 703 | - Function al Testing _Dev1 Gold 1 | ||
| 704 | 7034:EPIP PSS*1. | ||
| 705 | 0*227 - Un it Testing | ||
| 706 | |||
| 707 | |||
| 708 | |||
| 709 | 7035:EPIP PSS*1. | ||
| 710 | 0*227 - Fu nctional T esting | ||
| 711 | Dev1 Silve r1Unassign edLeckie, David R. ( Leidos) | ||
| 712 | |||
| 713 | |||
| 714 | |||
| 715 | Dev1 Gold1 Unassigned Leckie, Da vid R. (Le idos) | ||
| 716 |
|
||
| 717 | |||
| 718 | |||
| 719 | |||
| 720 | |||
| 721 |
|
||
| 722 | 0*227 | ||
| 723 | Master Tes t Plan | ||
| 724 | |||
| 725 | 9830:PSS | ||
| 726 | 0*227 | ||
| 727 | Master Tes t Plan | ||
| 728 | |||
| 729 | |||
| 730 | |||
| 731 | Test Suite Results | ||
| 732 | |||
| 733 | |||
| 734 | |||
| 735 | |||
| 736 | |||
| 737 | |||
| 738 | |||
| 739 | |||
| 740 | |||
| 741 | 489803 | ||
| 742 | |||
| 743 | Gold1 | ||
| 744 | EPIP PSS*1 . | ||
| 745 | 0*227 - Un it Testing _Dev1 Gold 1 | ||
| 746 | Testing | ||
| 747 | |||
| 748 | |||
| 749 | |||
| 750 | ID | ||
| 751 | Name | ||
| 752 | Test Suite | ||
| 753 | State | ||
| 754 | Owner | ||
| 755 | Created By | ||
| 756 | Completed | ||
| 757 | Status | ||
| 758 | Test Plan | ||
| 759 | State When Locked Run | ||
| 760 | 489798 | ||
| 761 | EPIP PSS*1 . | ||
| 762 | 0*277 - Re gression T esting_Dev 1 | ||
| 763 | 7036:EPIP PSS*1. | ||
| 764 | 0*277 - Re gression | ||
| 765 | Approved | ||
| 766 | Leckie, Da vid R. | ||
| 767 | (Leidos) | ||
| 768 | DNS | ||
| 769 | May 24, 20 18 | ||
| 770 | (UTC-05:00 ) | ||
| 771 | Passed | ||
| 772 | Approved | ||
| 773 | false7034: EPIP PSS*1 . | ||
| 774 | 0*227 - Un it Testing | ||
| 775 | |||
| 776 | |||
| 777 | |||
| 778 | |||
| 779 | ApprovedLe ckie, Davi d R. (Leid os) | ||
| 780 | |||
| 781 | |||
| 782 | |||
| 783 | |||
| 784 |
|
||
| 785 | |||
| 786 | |||
| 787 | |||
| 788 | |||
| 789 | PassedAppr ovedfalse | ||
| 790 | |||
| 791 | |||
| 792 | |||
| 793 | |||
| 794 | |||
| 795 | |||
| 796 | |||
| 797 | Gold1 | ||
| 798 | |||
| 799 | |||
| 800 | ID | ||
| 801 | Name | ||
| 802 | Test Suite | ||
| 803 | State | ||
| 804 | Owner | ||
| 805 | Created By | ||
| 806 | Completed | ||
| 807 | Status | ||
| 808 | Test Plan | ||
| 809 | State When Locked Run | ||
| 810 | 489854 | ||
| 811 | EPIP PSS*1 . | ||
| 812 | 0*227 - Fu nctional T esting_Dev 1 | ||
| 813 | 7035:EPIP PSS*1. | ||
| 814 | 0*227 - Fu nctional | ||
| 815 | Approved | ||
| 816 | Leckie, Da vid R. | ||
| 817 | (Leidos) | ||
| 818 | DNS | ||
| 819 | May 24, 20 18 | ||
| 820 | (UTC-05:00 ) | ||
| 821 | Passed | ||
| 822 | Approved | ||
| 823 | falseTesti ng | ||
| 824 | |||
| 825 | |||
| 826 | |||
| 827 | |||
| 828 | 489791 | ||
| 829 | |||
| 830 | Integratio n and Syst em Testing _ Dev1 Gol d1 | ||
| 831 | |||
| 832 | 0*227 - Co mponent In tegration and System Testing | ||
| 833 | |||
| 834 | |||
| 835 | EPIP PSS*1 . | ||
| 836 | 0*227 - Co mponent | ||
| 837 | 7037:EPIP PSS*1.Appr ovedLeckie , David R. (Leidos) | ||
| 838 | |||
| 839 |
|
||
| 840 | |||
| 841 | PassedAppr ovedfalse | ||
| 842 |
Araxis Merge (but not the data content of this report) is Copyright © 1993-2016 Araxis Ltd (www.araxis.com). All rights reserved.